TY - JOUR
T1 - Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease
AU - Savarino, E.
AU - Gemignani, L.
AU - Pohl, D.
AU - Zentilin, P.
AU - Dulbecco, P.
AU - Assandri, L.
AU - Marabotto, E.
AU - Bonfanti, D.
AU - Inferrera, S.
AU - Fazio, V.
AU - Malesci, A.
AU - Tutuian, R.
AU - Savarino, V.
PY - 2011/8
Y1 - 2011/8
N2 - Aliment Pharmacol Ther 2011; 34: 476-486 Summary Background Limited data are available regarding the frequency of oesophageal motility and bolus transit abnormalities in subgroups of patients with gastro-oesophageal reflux disease (GERD). Aim To assess oesophageal motility and bolus transit in endoscopically defined GERD subgroups. Methods Patients (N = 755) with typical reflux symptoms underwent upper endoscopy, conventional or impedance oesophageal manometry and/or impedance-pH testing. They were divided into: erosive oesophagitis (EO; N = 340), Barrett Oesophagus (BO; N = 106), non-erosive reflux disease (NERD; endoscopy-, abnormal pH and/or SAP/SI+; N = 239) and functional heartburn (FH; endoscopy-, normal pH and SAP/SI-; N = 70). Manometric patterns and bolus transit were defined according to previously published criteria. Results Increasing GERD severity was associated with decreased lower oesophageal sphincter resting pressure (P <0.05) and distal oesophageal amplitude (P <0.01), higher prevalence of hiatal hernia (P <0.01) and increased prevalence of ineffective oesophageal motility (P <0.01). Patients with EO and BO had a significantly lower percentage of complete bolus transit compared with NERD and FH (P <0.01). Overall, abnormal bolus transit (ABT) for liquid swallows was found in 12% of FH, 20% of NERD, 54% of EO and 56% of BO (P <0.01). Combined impedance-manometry showed abnormal oesophageal function in 4% of FH, 4% of NERD, 22% of EO and 21% of BO patients with normal oesophageal manometry. Conclusions Oesophageal motility abnormalities increase in parallel with the severity of GERD from NERD to EO and BO. Bolus transit abnormalities in severe reflux disease underscore the importance of impaired oesophageal function in the development of mucosal injury.
AB - Aliment Pharmacol Ther 2011; 34: 476-486 Summary Background Limited data are available regarding the frequency of oesophageal motility and bolus transit abnormalities in subgroups of patients with gastro-oesophageal reflux disease (GERD). Aim To assess oesophageal motility and bolus transit in endoscopically defined GERD subgroups. Methods Patients (N = 755) with typical reflux symptoms underwent upper endoscopy, conventional or impedance oesophageal manometry and/or impedance-pH testing. They were divided into: erosive oesophagitis (EO; N = 340), Barrett Oesophagus (BO; N = 106), non-erosive reflux disease (NERD; endoscopy-, abnormal pH and/or SAP/SI+; N = 239) and functional heartburn (FH; endoscopy-, normal pH and SAP/SI-; N = 70). Manometric patterns and bolus transit were defined according to previously published criteria. Results Increasing GERD severity was associated with decreased lower oesophageal sphincter resting pressure (P <0.05) and distal oesophageal amplitude (P <0.01), higher prevalence of hiatal hernia (P <0.01) and increased prevalence of ineffective oesophageal motility (P <0.01). Patients with EO and BO had a significantly lower percentage of complete bolus transit compared with NERD and FH (P <0.01). Overall, abnormal bolus transit (ABT) for liquid swallows was found in 12% of FH, 20% of NERD, 54% of EO and 56% of BO (P <0.01). Combined impedance-manometry showed abnormal oesophageal function in 4% of FH, 4% of NERD, 22% of EO and 21% of BO patients with normal oesophageal manometry. Conclusions Oesophageal motility abnormalities increase in parallel with the severity of GERD from NERD to EO and BO. Bolus transit abnormalities in severe reflux disease underscore the importance of impaired oesophageal function in the development of mucosal injury.
UR - http://www.scopus.com/inward/record.url?scp=79960555498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960555498&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2011.04742.x
DO - 10.1111/j.1365-2036.2011.04742.x
M3 - Article
C2 - 21671968
AN - SCOPUS:79960555498
VL - 34
SP - 476
EP - 486
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 4
ER -